Lorbrena is a prescription medicine for people living with anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer that has spread to other parts of the body and is no longer responding to alectinib or ceritinib or crizotinib and at least one other ALK inhibitor medicine.
Lorbrena works by inhibiting the ALK protein to help slow the growth or spread of ALK+ tumors that have spread to other parts of the body.
The most common side effects include swelling in arms, legs, hands and feet, numbness and tingling feeling in joints or arms and legs, difficulty thinking or confusion, difficulty breathing, tiredness, Weight gain, joint pain, changes in mood, feeling sad or anxious and diarrhea.
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs
Tell Us What You Think!
You must be logged in to post a comment.